| Recruiting | A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring NCT06660342 | Phathom Pharmaceuticals, Inc. | — |
| Not Yet Recruiting | Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis NCT06720610 | Indonesia University | Phase 4 |
| Completed | A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 2 NCT06391177 | Phathom Pharmaceuticals, Inc. | Phase 1 |
| Active Not Recruiting | A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it H NCT02615184 | Takeda | Phase 2 |
| Completed | A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease NCT05890001 | Braintree Laboratories | Phase 3 |
| Completed | A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis NCT05587309 | Braintree Laboratories | Phase 3 |
| Recruiting | Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esop NCT05267613 | AstraZeneca | Phase 3 |
| Completed | JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis NCT05443984 | Onconic Therapeutics Inc. | Phase 3 |
| Completed | A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 We NCT05055128 | Cinclus Pharma AG | Phase 2 |
| Completed | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008 NCT05050188 | Jiangsu Carephar Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Treatment Effect According to Timing of Administration of DWP14012 40 mg NCT04888819 | Konkuk University Medical Center | N/A |
| Unknown | Treatment Effect According to Timing of Administration of DWP14012 40 mg NCT04613895 | Daewoong Pharmaceutical Co. LTD. | N/A |
| Recruiting | Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adher NCT04255693 | Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology | N/A |
| Completed | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis NCT04124926 | Phathom Pharmaceuticals, Inc. | Phase 3 |
| Completed | Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD) NCT03943992 | Yooyoung Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease NCT03736369 | Daewoong Pharmaceutical Co. LTD. | Phase 3 |
| Unknown | Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GER NCT03228407 | McGuire Research Institute | N/A |
| Terminated | Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis NCT02873702 | Takeda | Phase 3 |
| Completed | Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis NCT03006874 | HK inno.N Corporation | Phase 3 |
| Completed | Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety NCT02679508 | Takeda | Phase 4 |
| Completed | Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis NCT02456935 | HK inno.N Corporation | Phase 3 |
| Completed | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis NCT02388737 | Takeda | Phase 3 |
| Completed | A Study to Compare the Pharmacokinetic Characteristics of CJ-12420 NCT02995239 | HK inno.N Corporation | Phase 1 |
| Completed | Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis NCT02388724 | Takeda | Phase 3 |
| Completed | Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets NCT02096458 | Takeda | Phase 1 |
| Completed | Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis NCT02028663 | HK inno.N Corporation | Phase 2 |
| Completed | Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or NCT01865825 | Mayo Clinic | — |
| Completed | Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Mainten NCT01642615 | Takeda | Phase 2 |
| Completed | A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TA NCT01630746 | Takeda | Phase 3 |
| Completed | A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Sa NCT01499368 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Completed | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagi NCT01459367 | Takeda | Phase 3 |
| Completed | Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis NCT01452776 | Takeda | Phase 3 |
| Completed | Efficacy Study of Ilaprazole to Treat Erosive Esophgitis NCT01509261 | Il-Yang Pharm. Co., Ltd. | Phase 3 |
| Completed | Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole The NCT01874535 | Chang Gung Memorial Hospital | Phase 4 |
| Completed | To Learn How Bone Structure and Bone Mass Change After Long-term PPI Use NCT01306799 | University of Pennsylvania | — |
| Completed | Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis NCT00586963 | Mayo Clinic | — |
| Completed | Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study NCT00693225 | Yvonne Romero | Phase 4 |
| Completed | Esomeprazole for Treatment of GERD in Pediatric Patients NCT00228527 | AstraZeneca | Phase 4 |
| Completed | NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis NCT00206180 | AstraZeneca | Phase 4 |
| Completed | A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Trea NCT00641602 | AstraZeneca | Phase 4 |
| Completed | Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once NCT00644735 | AstraZeneca | Phase 4 |
| Completed | Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis NCT01452698 | Takeda | Phase 3 |